ZBIO (Zenas BioPharma) Notes Receivable: $0.00 Mil (As of Mar. 2026)


ZBIO Zenas BioPharma Inc ZBIO
12 GF Score
Price $28.73
! 1 Warning Sign
View Full Analysis

What is Zenas BioPharma Notes Receivable?

Zenas BioPharma ZBIO -2.34% 12 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates ZBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Zenas BioPharma's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Zenas BioPharma Notes Receivable Related Terms

Zenas BioPharma Notes Receivable Historical Data

* Premium members only.

The historical data trend for Zenas BioPharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma Notes Receivable Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ZBIO
12GF Score
Zenas BioPharma Inc ZBIO
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenas BioPharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Zenas BioPharma (ZBIO) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Zenas BioPharma and its competitors.
Is Zenas BioPharma's Notes Receivable too high?
Zenas BioPharma's current Notes Receivable is $0.00 Mil. Overall, Zenas BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's Notes Receivable compare to AKTS and MLTX?
Zenas BioPharma's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Zenas BioPharma and its competitors. Zenas BioPharma's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Zenas BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
12GF Score

Get the complete analysis for ZBIO

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.73
Price